Cervical cancer remains a significant global health concern, recognised as the fourth most common cancer in women worldwide.
The data highlights a critical challenge: in 2022 alone, approximately 660,000 new cases were reported, leading to the tragic loss of around 350,000 women globally.
World Cervical Cancer Elimination Day, observed on November 17th, underscores the urgency of addressing this disease.
A major driver of cancer is persistent human papillomavirus (HPV) infection.
Disparities in incidence and mortality are stark, with low- and middle-income countries bearing the highest burden. These inequities stem largely from limited access to essential prevention and treatment measures, including HPV vaccination, screening, and comprehensive care.
Critically, women living with HIV are six times more likely to develop cervical cancer. The good news is that prevention and cure are possible.
HPV vaccination is highly effective in preventing the disease, and early diagnosis combined with prompt treatment can cure cervical cancer. Effective screening and treating pre-cancer lesions are also vital, readily available prevention methods.
